» Articles » PMID: 30779243

Investigation of Human ApoB48 Metabolism Using a New, Integrated Non-steady-state Model of ApoB48 and ApoB100 Kinetics

Overview
Journal J Intern Med
Specialty General Medicine
Date 2019 Feb 20
PMID 30779243
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Triglyceride-rich lipoproteins and their remnants have emerged as major risk factors for cardiovascular disease. New experimental approaches are required that permit simultaneous investigation of the dynamics of chylomicrons (CM) and apoB48 metabolism and of apoB100 in very low-density lipoproteins (VLDL).

Methods: Mass spectrometric techniques were used to determine the masses and tracer enrichments of apoB48 in the CM, VLDL and VLDL density intervals. An integrated non-steady-state multicompartmental model was constructed to describe the metabolism of apoB48- and apoB100-containing lipoproteins following a fat-rich meal, as well as during prolonged fasting.

Results: The kinetic model described the metabolism of apoB48 in CM, VLDL and VLDL . It predicted a low level of basal apoB48 secretion and, during fat absorption, an increment in apoB48 release into not only CM but also directly into VLDL and VLDL . ApoB48 particles with a long residence time were present in VLDL, and in subjects with high plasma triglycerides, these lipoproteins contributed to apoB48 measured during fasting conditions. Basal apoB48 secretion was about 50 mg day , and the increment during absorption was about 230 mg day . The fractional catabolic rates for apoB48 in VLDL and VLDL were substantially lower than for apoB48 in CM.

Discussion: This novel non-steady-state model integrates the metabolic properties of both apoB100 and apoB48 and the kinetics of triglyceride. The model is physiologically relevant and provides insight not only into apoB48 release in the basal and postabsorptive states but also into the contribution of the intestine to VLDL pool size and kinetics.

Citing Articles

Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review.

Zubiran R, Neufeld E, Dasseux A, Remaley A, Sorokin A Cardiol Ther. 2024; 13(3):465-491.

PMID: 39031302 PMC: 11333429. DOI: 10.1007/s40119-024-00376-3.


HNF4A-Bridging the Gap Between Intestinal Metaplasia and Gastric Cancer.

Zhao Y, Tang H, Xu J, Sun F, Zhao Y, Li Y Evol Bioinform Online. 2024; 20:11769343241249017.

PMID: 38680615 PMC: 11047246. DOI: 10.1177/11769343241249017.


Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.

Packard C, Pirillo A, Tsimikas S, Ference B, Catapano A Cardiovasc Res. 2023; 119(18):2843-2857.

PMID: 38039351 PMC: 11484501. DOI: 10.1093/cvr/cvad177.


Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.

Taskinen M, Matikainen N, Bjornson E, Soderlund S, Inkeri J, Hakkarainen A Diabetologia. 2023; 66(12):2307-2319.

PMID: 37775612 PMC: 10627993. DOI: 10.1007/s00125-023-06008-0.


Effects of Early Life Oral Arsenic Exposure on Intestinal Tract Development and Lipid Homeostasis in Neonatal Mice: Implications for NAFLD Development.

Yang X, Weber A, Mennillo E, Secrest P, Chang M, Wong S Environ Health Perspect. 2023; 131(9):97001.

PMID: 37668303 PMC: 10478510. DOI: 10.1289/EHP12381.


References
1.
Smith D, Watts G, Mamo J . Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest. 1999; 29(3):204-9. DOI: 10.1046/j.1365-2362.1999.00431.x. View

2.
Karpe F, Hamsten A . Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res. 1994; 35(7):1311-7. View

3.
Lovegrove J, Isherwood S, Jackson K, Williams C, GOULD B . Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim Biophys Acta. 1996; 1301(3):221-9. DOI: 10.1016/0005-2760(96)00039-2. View

4.
Gaudet D, Alexander V, Baker B, Brisson D, Tremblay K, Singleton W . Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015; 373(5):438-47. DOI: 10.1056/NEJMoa1400283. View

5.
Pang J, Chan D, Hamilton S, Tenneti V, Watts G, Barrett P . Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2015; 18(4):384-91. DOI: 10.1111/dom.12622. View